A trial is currently being conducted to add PI3K inhibitor therapy to trastuzumab and pertuzumab in advanced HER2+ breast cancer and PIK3CA-mutant breast cancer (NCT04108858). This evidence concerns the gene ERBB2 and breast carcinoma.